StockData
Evommune, Inc. logo

Evommune, Inc. (EVMN) stock

EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$7.02−0.08 (-1.13%)

Close on Nov 17, 2026Market cap $254.77MP/E –Yield –

Earnings

Evommune's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 4, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
–
– on a year earlier
EPS, Q3 FY2026
-$0.85
-$8.07 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Evommune's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 4, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 12, 2026after the close––-$0.85Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026after the close––-$0.89Release
Q1 FY2026ended Mar 31, 2026May 7, 2026after the close––-$0.64Release
Q4 FY2025ended Dec 31, 2025Mar 5, 2026after the close$0–-$1.43Release
Q3 FY2025ended Sep 30, 2025Dec 11, 2025after the close$10.00M–-$8.07Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Evommune has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Evommune puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Evommune filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Update
  5. Update
  6. Update
  7. Update
  8. Update
  9. Update
  10. Update
  11. Results
  12. Update
  13. Update
  14. Results
  15. Results

See a number that looks wrong?